Adult Dosing
Remission induction and remission consolidation of acute nonlymphocytic leukemias
- 2 mg/kg PO qd
- If no improvement and no serious toxicity after 4 weeks, may increase dose to 3 mg/kg PO qd
Notes:- Refer package insert for toxicity-related dose adjustments
- Decrease dose if patient is TPMT-deficient
Pediatric Dosing
Remission induction and remission consolidation of acute nonlymphocytic leukemias
- 2 mg/kg PO qd
- If no improvement and no serious toxicity after 4 weeks, may increase dose to 3 mg/kg PO qd
Notes:- Refer package insert for toxicity-related dose adjustments
- Decrease dose if patient is TPMT-deficient
[Outline]
See Supplemental Patient Information
- Physicians experienced with the risk of thioguuanine and having knowledge of acute nonlymphocytic leukemias should administer this drug. Not recommended for maintenance therapy or for prolonged use due to risk of liver toxicity associated with vascular endothelial damage
- Liver toxicity has been reported, especially in children receiving thioguanine as part of maintenance therapy for acute lymphoblastic leukemia. Discontinue therapy in patients with evidence of liver toxicity as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal
- Elevations of liver enzymes, hypertension, thrombocytopenia out of proportion with neutropenia and splenomegaly have also been reported in association with liver toxicity
- Dose related toxicity such as bone marrow suppression manifested by anemia, leukopenia, thrombocytopenia, or any combination of these have occurred; withdraw the therapy at the first sign of an abnormally large fall in any of the formed elements of the blood
- Rapid bone marrow suppression has been reported after start of therapy in patients with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT). Consider dose reduction to avoid the development of life-threatening bone marrow suppression and closely monitor clinical and hematologic parameters in such patients. Bone marrow suppression may worsen if coadministered with drugs that inhibit TPMT
- Evaluate Hb concentration, WBC count, differential count, and quantitative platelet count frequently during the treatment. Bone marrow examination should be done for evaluation of marrow status. CBC test is done more frequently during the induction phase of acute leukemia in order to evaluate the effect of the therapy
- Life-threatening infections and bleeding have been reported as consequences of thioguanine-induced granulocytopenia and thrombocytopenia
- Therapy may cause fetal harm when administered to a pregnant woman
- Jaundice has been reported in patients with leukemia receiving thioguanine
Cautions: Use cautiously in
- Hepatic disease
- Thiopurine methyltransferase (TPMT) deficiency
- Concurrent hepatotoxic agents
- Elderly patients
- Prolonged use
- Avoid pregnancy
Supplemental Patient Information
- Advise women of childbearing potential to avoid becoming pregnant during therapy
Pregnancy Category:D
Breastfeeding: Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Tabloid 40 MG TABS [Bottle] (GLAXO SMITH KLINE)
25 mg = $247.98
50 mg = $489.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Tabloid 40 MG Oral Tablet
Ingredient(s): Thioguanine
Imprint: WELLCOME;U3B
Color(s): Green
Shape: Round
Size (mm): 9.00
Score: 2
Inactive Ingredient(s): acacia / lactose monohydrate / magnesium stearate / starch, potato / stearic acid
Drug Label Author:
GlaxoSmithKline LLC
DEA Schedule:
Non-Scheduled
